Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pitavastatin + valsartan
- Development stage
- Preclinical
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose combination medication containing pitavastatin (a statin) and valsartan (an angiotensin II receptor blocker). Pitavastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis, while valsartan blocks angiotensin II receptor type 1 to lower blood pressure. This combination targets both hyperlipidemia and hypertension simultaneously.
- Brand names
- LivaloVLivaloVALivasartan
- Other names
- JW0101 + C2102pitavastatin/valsartanvalsartan/pitavastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on pitavastatin + valsartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pitavastatin + valsartan.